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Objectives. We sought to investigate whether functional abnor-
malities in coronary vasomotion exist in young adults by studying
15 men (age 31  8 years [mean  SD]) with familial hypercho-
lesterolemia (FH) and a matched group of 20 healthy control
subjects.
Background. Precursors of morphologic coronary artery dis-
ease are known to be present in adolescents and young adults with
a high risk factor proﬁle.
Methods. Myocardial blood ﬂow was measured at the basal
state and during dipyridamole-induced hyperemia using positron
emission tomography and oxygen-15–labeled water.
Results. Serum total and low density lipoprotein cholesterol
concentrations were higher in the patients than in the control
subjects (mean  SD): 7.7  1.9 versus 5.3  1.5 mmol/liter
(298  73 vs. 205  58 mg/dl) and 6.1  1.8 versus 3.5  1.4
mmol/liter (236  70 vs. 135  54 mg/dl), respectively (both p <
0.001). The baseline myocardial blood ﬂow was similar in the
patients and control subjects: 0.92  0.24 versus 0.83  0.13 ml/g
per min, respectively (p  0.21). A signiﬁcant increase in ﬂow was
observed in both groups after dipyridamole infusion, but the ﬂow
at maximal vasodilation was 29% lower in the patients: 3.19 
1.59 versus 4.49  1.27 ml/g per min (p  0.011). Consequently,
coronary ﬂow reserve (the ratio of hyperemia ﬂow to basal ﬂow)
was 35% lower in the patients than in the control subjects: 3.5 
1.6 versus 5.4 1.5 (p 0.0008). Total coronary resistance during
hyperemia was higher in the patients than in the control subjects:
36  25 versus 21  10 mm Hg/min per g per ml (p  0.045).
Coronary ﬂow reserve was inversely associated with serum total
cholesterol concentration: r  0.43 (p  0.009).
Conclusions. Coronary ﬂow reserve is reduced in young men
with FH, and, consequently, coronary resistance during hyper-
emia is increased. The results demonstrate very early impairment
of coronary vasomotion in hypercholesterolemic patients.
(J Am Coll Cardiol 1996;28:1705–11)
1996 by the American College of Cardiology
The disease process of atherosclerosis begins in childhood.
Lipid deposits and fatty streaks are found in the coronary
arteries by adolescence (1,2). Endothelial dysfunction is an
early phenomenon in atherogenesis. In experimental animal
studies endothelial dysfunction and reduced vasodilatory re-
serve have been detected before plaque formation (3,4). In
humans, impaired endothelium-dependent vasorelaxation in
large epicardial coronary arteries has been found in patients
with coronary artery disease (5). Abnormal ﬂow response has
also been detected in mildly stenosed coronary arteries (6) and
in nonstenosed coronary arteries (7) in patients with coronary
artery disease. Furthermore, it has been found that abnormal
coronary ﬂow reserve exists in middle-aged asymptomatic
subjects at high risk for coronary artery disease (8). However,
it is not known whether these abnormalities are present
already in young adults with risk factors for coronary artery
disease.
Positron emission tomography (PET) can be used to mea-
sure regional myocardial blood ﬂow accurately without inva-
sive and potentially risky procedures (9–12). The ﬂow response
to dipyridamole reﬂects endothelium-dependent vasodilation
(13,14). Measuring myocardial blood ﬂow at rest and after
dipyridamole or adenosine administration allows calculation of
coronary ﬂow reserve, an integrating measure of endothelial
function and vascular smooth muscle relaxation. Additionally,
the method yields a quantitative estimation of coronary resis-
tance.
The purpose of this study was to investigate whether
coronary ﬂow abnormalities exist in young asymptomatic men
with familial hypercholesterolemia (FH). Flow was measured
using PET and oxygen-15–labeled water ([15O]H2O). The
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results of patients with FH were compared to those of a
matched group of healthy volunteers.
Methods
Patients. Fifteen men with heterozygous FH were enrolled
in this study (mean [SD] age 31  7.5 years). No subject had
a clinical history or evidence of coronary artery disease or
other cardiac disease, diabetes or systemic hypertension, and
none of them were current smokers. One patient (Patient 34,
Table 1) had previously underwent coronary angiography to
exclude signiﬁcant epicardial coronary artery disease. All pa-
tients had at least one ﬁrst-degree relative with hypercholes-
terolemia. Familial hypercholesterolemia was veriﬁed by lym-
phocyte testing in ﬁve men; seven men had either clinical signs
of tendon xanthomas or a positive ﬁnding on ultrasound of the
Achilles tendon; and three men had at least one ﬁrst-degree
relative with hypercholesterolemia and tendon xanthomata.
The patients were selected from the patient registry of Turku
University Central Hospital. Twelve patients were taking
cholesterol-lowering medication for several years. Eight pa-
tients were taking lovastatin, one lovastatin in combination
with colestipol, one lovastatin in combination with acipimox,
one bezaﬁbrate and one simvastatin in combination with
cholestyramine. Three men were only on diet therapy. To rule
out signiﬁcant coronary artery disease, stress echocardio-
graphic examination was performed for those subjects with low
coronary perfusion values (3). All these men had normal
exercise capacity, were asymptomatic during the test, had no
diagnostic ST segment changes on the electrocardiogram
(ECG), and had no wall motion disturbances either at rest or
after exercise test. A group of 20 healthy volunteers matched
for age and body mass index (BMI) served as the control
group. The subject characteristics are shown in Table 1.
Study design. Patients continued their normal medication
during the study. The study subjects were instructed to avoid
all food and drink (including coffee, tea and soft-drinks) 6 h
before the PET scan. Myocardial perfusion was measured
twice, once at rest and once after administration of dipyrida-
mole. Heart rate and blood pressure were monitored during
the studies to calculate the rate-pressure product. The ECG
was monitored during the PET studies continuously. The study
protocol was accepted by the Ethical Committee of the Turku
University Central Hospital. Each subject gave a written
informed consent.
Production of [15O]CO and [15O]H2O. For production of
15O a low energy deuteron accelerator Cyclone 3 was used (Ion
Beam Application Inc., Louvain-la-Neuve, Belgium). Oxygen-
15–labeled carbon monoxide ([15O]CO) was produced in a
conventional way (15). Oxygen-15–labeled water was produced
using dialysis techniques in a continuously working water
module (16). Monoxide and water production was 2.5 and
1.7 GBq/min, respectively. Sterility and pyrogenity tests for
water and chromatographic analysis for gases were performed
to verify the purity of the products.
Image acquisition, processing and corrections. The patients
were positioned supine in a 15-slice ECAT 931/08-12 tomo-
graph (Siemens/CTI Inc.) with a measured axial resolution of
6.7 mm and 6.5 mm in plane. To correct for photon attenua-
tion, a transmission scan was performed for 20 min before the
emission scan with a removable ring source containing
germanium-68 (total counts 15 to 30  106/plane).
After the transmission scan, the subjects’ nostrils were
closed and they inhaled [15O]CO for 2 min through a three-
way inhalation ﬂap-valve (0.14% carbon monoxide mixed with
room air, mean dose 3,400  410 MBq (92  11 mCi). After
the inhalation, 2 min was allowed for carbon monoxide to
combine with hemoglobin in red blood cells before a static scan
for 4 min was started. During the scan period, three blood
samples were drawn at 2-min intervals and blood radioactivity
was measured immediately with a well-type NaI(Tl) detector
(Bicron 3MW3/3). A 10-min period was allowed for [15O]CO
radioactive decay before the ﬂow measurements.
Flow was measured at baseline and 2 min after the end of
intravenous administration of dipyridamole (0.56 mg/kg body
weight over 4 min). We injected 1,650  110 MBq (45 
3 mCi) of [15O]H2O intravenously for 2 min (1,670 110 MBq
at baseline and 1,630  110 MBq after dipyridamole) and
started dynamic scanning for 6 min (6 5 s, 6 15 s, 8 30 s).
All data were corrected for dead time, decay and photon
attenuation and reconstructed in a 128  128 matrix. The ﬁnal
in-plane resolution in reconstructed and Hann-ﬁltered (0.3 Hz)
images was 9.5 mm full-width half-maximum.
Calculation of regional blood ﬂow. Large regions of interest
(ROIs) were placed on four representative transaxial ventric-
ular slices in each study covering the anterior and lateral free
wall of the left ventricle. The ROIs were drawn on the images
obtained at rest and copied to the images obtained after
dipyridamole administration. Values of regional myocardial
blood ﬂow (expressed in milliliters per gram of tissue per
minute) were calculated according to a previously published
method employing the single-compartment model (17,18). The
arterial input function was obtained from the left ventricular
time-activity curve using a previously validated method (19), in
which corrections were made for the limited recovery of the
left ventricular ROI and the spillover from the myocardial
signals. The mean blood ﬂow values at baseline and after
dipyridamole administration were calculated and used in fur-
Abbreviations and Acronyms
BMI  body mass index
ECG  electrocardiogram
FH  familial hypercholesterolemia
HDL-C  high density lipoprotein cholesterol
LDL-C  low density lipoprotein cholesterol
O15  oxygen-15
[O15]CO  oxygen-15–labeled carbon monoxide
[O15]H2O  oxygen-15–labeled water
PET  positron emission tomography, positron emission
tomographic
ROI  region of interest
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ther analysis. Qualitative analysis of the PET data did not reveal
any regional differences in the distribution of blood ﬂow. There-
fore, to enhance accuracy and statistics of ﬂowmeasurements, the
average ﬂow of global left ventricular myocardiumwas calculated,
and no detailed regional analysis was carried out.
The coronary ﬂow reserve was deﬁned as a ratio of the
myocardial blood ﬂow after dipyridamole to the ﬂow at baseline.
In addition, coronary resistance values were calculated both at
baseline and after dipyridamole by dividing the mean arterial
blood pressure by the respective coronary ﬂow value.
Analytical procedures. All venous blood samples were
taken after 12 h of fasting. Plasma glucose was determined by
the glucose oxidase method (20). Serum insulin was measured
by radioimmunoassay kit (Pharmacia, Uppsala, Sweden). All
lipid determinations were done in the laboratory of Turku
University Hospital. Standard enzymatic methods were used in
serum total cholesterol and triglycerides (Boehringer) concen-
tration measurements. Serum high density lipoprotein choles-
terol (HDL-C) concentration was measured from the serum
supernatant after precipitation of very low density lipoprotein
(LDL) and LDL subfractions with dextran sulfate and magne-
sium chloride (21). The concentration of LDL-C was calcu-
lated using the Friedewald formula (22).
Statistical analysis. The results are presented as mean
value SD. Body mass index was calculated from the formula:
BMI  Weight (kg)/(Height [m])2. Comparisons between the
two groups were performed by the t test. Pearson’s correlation
coefﬁcients were calculated to study the associations between
Table 1. Characteristics and Results of the Study Subjects
Subject No./
Age (yr) BMI
TC
(mmol/liter)*
HDL-C
(mmol/liter)*
TG
(mmol/liter)†
Basal
Flow
(ml/g per min)
Hyperemic
Flow
(ml/g per min)
Flow
Reserve Medication
Control Subjects (n  20)
1/32 24.3 3.2 1.20 0.6 0.82 4.55 5.55
2/34 25.0 3.5 1.47 0.7 0.98 5.60 5.71
3/36 24.3 2.8 1.36 0.7 0.79 4.41 5.58
4/34 25.1 3.5 1.26 0.4 0.73 4.79 6.56
5/33 24.4 4.8 1.84 0.7 0.86 4.63 5.38
6/38 23.6 5.7 1.86 0.6 0.81 4.27 5.27
7/29 25.7 4.3 1.30 0.8 0.67 3.44 5.13
8/29 23.7 4.4 1.76 0.7 0.68 5.74 8.44
9/32 22.9 7.5 1.13 1.6 0.89 3.94 4.43
10/33 27.4 4.9 1.12 1.2 0.74 5.07 6.85
11/37 23.1 7.8 1.13 2.2 1.05 6.13 5.84
12/35 25.1 5.7 0.72 3.7 0.91 5.61 6.16
13/37 27.6 6.7 1.14 1.1 1.13 5.47 4.84
14/37 27.5 7.2 1.18 2.6 0.66 1.74 2.64
15/34 23.9 4.7 0.99 1.3 0.79 1.86 2.35
16/32 24.9 4.5 0.78 1.5 0.91 5.50 6.04
17/35 25.1 6.8 1.37 0.7 0.78 4.59 5.88
18/29 23.1 5.8 1.02 1.2 0.84 4.91 5.85
19/32 25.3 6.8 1.14 1.0 0.87 2.36 2.71
20/35 23.2 5.7 1.04 0.9 0.69 5.26 7.62
Hypercholesterolemic Patients (n  15)
21/26 22.4 6.0 1.03 0.8 0.95 1.45 1.53 LO
22/31 27.4 6.1 1.25 1.0 0.86 3.45 4.01 SI, CHO
23/30 22.5 10.2 1.05 1.7 0.83 4.66 5.61 LO
24/27 28.7 6.8 0.67 1.3 0.98 5.00 5.10 LO
25/36 32.9 12.8 1.07 1.4 0.86 1.79 2.08 —
26/31 25.4 9.4 1.38 1.0 0.75 2.86 3.81 —
27/35 26.3 7.2 1.11 1.3 0.67 2.16 3.22 LO
28/39 25.4 7.8 0.76 0.9 0.94 5.14 5.46 —
29/19 23.4 6.3 1.01 1.2 1.00 2.96 2.96 LO
30/32 24.2 6.9 0.87 1.3 1.12 6.05 5.40 LO
31/31 23.8 8.4 1.19 1.0 1.06 3.78 3.57 BEZ
32/22 27.5 7.3 0.85 1.5 0.75 1.59 2.12 LO, COL
33/42 28.7 6.8 0.81 2.3 1.59 1.65 1.04 LO
34/44 26.8 7.6 0.98 1.7 0.52 0.95 1.83 LO, ACI
35/20 27.2 5.9 0.81 1.1 0.90 4.36 4.84 LO
*To convert values to mg/dl, multiply by 38.67. †To convert values to mg/dl, multiply by 88.57. ACI  acipimox; BEZ  bezaﬁbrate; BMI  body mass index;
CHO  cholestyramine; COL  colestipol; HDL-C  high density lipoprotein cholesterol; LO  lovastatin; SI  simvastatin; TC  total cholesterol.
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ﬂow reserve and lipid variables. Values p  0.05 were inter-
preted as statistically signiﬁcant. All statistical analyses were
performed with the SAS statistical program package (SAS
Institute Inc.).
Results
Patient characteristics. The characteristics of the subjects
are shown in Table 1. There were no differences in age (31 
8 versus 34  3 years, p  0.21) and BMI (26.2  2.8 versus
24.8  1.4, p  NS) between the patients with FH and the
control subjects. Serum total cholesterol concentration of
7.7  1.9 versus 5.3  1.5 mmol/liter (298  73 versus 205 
58 mg/dl) and LDL-C concentration of 6.1  1.8 versus 3.5 
1.4 mmol/liter (236  70 versus 135  54 mg/dl) were
signiﬁcantly higher, and HDL-C values of 0.99  0.20 versus
1.24  0.31 mmol/liter (39  8 versus 46  12 mg/dl) were
lower in the patients with FH as compared with control
subjects. There were no difference in serum triglycerides (1.3
0.4 versus 1.2  0.8 mmol/liter, p  0.67), glucose (5.2  0.7
versus 5.2  0.4 mmol/liter, p  0.86) or insulin (9.9  3.8
versus 9.2  3.1 mU/liter, p  0.54) concentrations between
the subject groups.
Hemodynamic measurements during PET. Dipyridamole
administration induced a signiﬁcant increase in heart rate and
rate-pressure product (Table 2). There were no signiﬁcant
differences between the patients with FH and control subjects
in the heart rate and systemic blood pressure either at baseline
or during maximal vasodilation (Table 2). Consequently, the
rate-pressure products and their changes were also similar
between the two groups.
Myocardial blood ﬂow. Basal myocardial blood ﬂow was
similar in the patients with FH and the control subjects: 0.92
0.24 versus 0.83  0.13 ml/g per min (p  0.21). A signiﬁcant
increase in ﬂow was obtained in both subject groups by
dipyridamole infusion, but the ﬂow at maximal vasodilation
was signiﬁcantly lower in the patients with FH: 3.19  1.59
versus 4.49  1.27 ml/g per min (p  0.011) (Fig. 1).
Consequently, coronary ﬂow reserve was signiﬁcantly lower in
the patients with FH than in the control subjects: 3.5  1.6
versus 5.4  1.5 (p  0.0008) (Fig. 2). Individual values for
these variables are displayed in Table 1. In pooled data the
coronary ﬂow reserve correlated inversely with total choles-
terol (r  0.43, p  0.009) and (r  0.44, p  0.009)
LDL-C concentrations (Fig. 3). The HDL/total cholesterol
ratio was positively associated with coronary ﬂow reserve (r 
0.45, p  0.007). All subjects with an HDL/total cholesterol
ratio above 0.2 demonstrated coronary ﬂow reserve 5. In
contrast, those with HDL/total cholesterol ratios 0.2 showed
commonly very low ﬂow reserve values (Fig. 3). No signiﬁcant
correlations between the ﬂow reserve and age, serum insulin,
triglyceride or plasma glucose concentrations were detected.
Baseline coronary resistance was similar in both study
groups: 94  25 and 99  18 mm Hg/min per g per ml in the
patients and control subjects, respectively (p  0.48). During
hyperemia coronary resistance was higher in the patients with
Figure 1. Myocardial blood ﬂow at baseline and during hyperemia.
Signiﬁcantly lower ﬂow was detected in patients with FH (solid bars)
than in control subjects (hatched bars) during hyperemia.
Table 2. Hemodynamic Data During Positron Emission Tomographic Scanning [mean (SD)]
Heart Rate
(beats/min)
Systolic Blood Pressure
(mm Hg)
Diastolic Blood Pressure
(mm Hg)
Rate-Pressure Product
(systolic, mm Hg  beats/min)
Change
(%)Rest Dipyr Rest Dipyr Rest Dipyr Rest Dipyr
Patients with FH (n  15) 63 (12) 82 (11)* 121 (9) 125 (15) 62 (10) 63 (13) 7,680 (1,740) 10,300 (1,800)* 36 (20)
Control subjects (n  20) 61 (9) 86 (12)* 116 (12) 118 (16) 63 (6) 68 (13) 7,060 (1,280) 10,100 (2,200)* 42 (29)
*p  0.05, baseline versus after dipyridamole administration; p  NS for all between-group comparisons. Dipyr  after dipyridamole administration.
Figure 2. Coronary ﬂow reserve in patients with FH and control
subjects.
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FH than in control subjects: 36  25 versus 21  10 mm
Hg/min per g per ml (p  0.045) (Fig. 4).
Discussion
This study demonstrates reduced maximal coronary ﬂow
and ﬂow reserve after dipyridamole administration in young
men with FH. Accordingly, total coronary resistance during
hyperemia was higher in patients than in matched healthy
control subjects. The measured coronary ﬂow reserve corre-
lated with the actual serum cholesterol concentrations, further
supporting that the abnormal serum lipid proﬁle is associated
with the reduced coronary ﬂow response.
Previously, abnormal coronary ﬂow response to acetylcho-
line or dipyridamole was demonstrated in a variety of patho-
logic settings such as coronary artery disease (23), syndrome X
(24) and hypertrophic cardiomyopathy (25). In patients with
coronary artery disease, abnormalities in ﬂow response to
vasodilating agents have been found in mildly stenosed (6) and
even in nonstenosed coronary arteries (7). Recently, Dayanikli
et al. (8) studied asymptomatic middle-aged subjects with a
family history of coronary artery disease and high risk lipid
proﬁles using PET. Reduced coronary ﬂow reserve was de-
tected in the high risk patients when compared with the control
group. Although previous studies have found that endothelial
dysfunction exists in the peripheral arteries of children and
adults at risk of atherosclerosis (26), abnormalities in the
coronary vasodilatory function have not been documented in
young subjects. The results of our study suggest a very early
disturbance of coronary ﬂow reserve in patients with FH.
Myocardial blood ﬂow, ﬂow reserve and vascular resis-
tance. The measured coronary ﬂow values at baseline in this
study are concordant with the results of previous studies using
PET (7,8,23). In those studies the mean ﬂow at maximal
vasodilation ranged from 2.6 to 3.7 ml/g per min and the
coronary ﬂow reserve from 3.2 to 4.3. Thus, in this study the
respective values appear slightly higher in the young control
subjects (maximal ﬂow 4.49 ml/g per min, reserve 5.4), but are
comparable in the patients with FH (ﬂow 3.19 ml/g per min,
ﬂow reserve 3.5). Correspondingly, the total coronary resis-
tance values at baseline were similar in both subject groups and
comparable to those obtained by Uren et al. (23) using similar
methods. In that study the mean coronary resistance during
hyperemia was 57 mm Hg/min per g per ml in patients with
coronary artery disease and 32 mm Hg/min per g per ml in
normal subjects (age 57 years). The respective values in our
Figure 3. Scatterplots showing the relations between coronary perfu-
sion reserve and lipid variables. Signiﬁcant correlation coefﬁcients
were found in the pooled data between coronary perfusion reserve and
LDL-C (r0.44, p 0.009), total cholesterol (r0.43, p 0.009)
and HDL-C/total cholesterol ratio (r  0.45, p  0.007). Solid
circles  patients with FH; open circles  control subjects.
Figure 4. Total coronary resistance at baseline and during hyperemia.
No difference in resistance was detected at baseline between the
subject groups. However, during hyperemia, coronary resistance was
higher in the patients with FH than in control subjects.
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study were 36 mm Hg/min per g per ml in the patients with FH
and 21 mm Hg/min per g per ml in the control subjects. Thus,
the coronary ﬂow reserve and coronary resistance in the
patients with FH in this study were comparable to those of
older normal subjects. Coronary resistance appears clearly
higher in the stenosis-associated regions in the patients with
coronary artery disease (23).
Vascular reactivity and serum cholesterol concentration.
Cholesterol-lowering therapy may improve the endothelium-
dependent relaxation or vasodilatory reserve in patients with
known coronary artery disease (27–30). Recovery of
endothelium-dependent vasodilation has also been detected in
hypercholesterolemic patients without angiographically evi-
dent atherosclerosis (31). In this study most of the patients
with FH had been on cholesterol-lowering agents for several
years. The actual serum cholesterol concentrations were still
moderately elevated. Thus, although the cholesterol-lowering
therapy may have already improved coronary vasodilatory
capacity, the treatment had not been effective enough to allow
complete recovery of ﬂow reserve. Further studies are needed
to determine whether complete normalization of serum cho-
lesterol concentrations by more aggressive lipid-lowering ther-
apy could completely reverse the abnormal myocardial perfu-
sion reserve.
Dipyridamole as a vasoactive agent. In this study dipyrid-
amole was used as a vasodilating agent to test coronary
function. Dipyridamole increases interstitial adenosine con-
centrations in vascular smooth muscle, leading to relaxation of
coronary resistance vessels. It has been postulated that in-
creased shear stress associated with increased ﬂow will induce
the release of vasodilating substances from endothelial cells
(32), and thus elicits more prominent vasodilation in the
vessels with preserved endothelial function. Indeed, the coro-
nary ﬂow response to dipyridamole or adenosine has been
found to relate to endothelium-dependent vasodilation
(13,14). Thus, the coronary ﬂow response to dipyridamole can
be used as an integrating measure of endothelial function and
vascular smooth muscle relaxation.
Study limitations. In this study only men with familial type
of hypercholesterolemia were enrolled. We do not know
whether the same results can be extrapolated to female
subjects of similar age. The cholesterol concentrations in
untreated patients with FH are usually very high. Although our
patients had been on cholesterol-lowering therapy for several
years and the present serum cholesterol values were only
moderately increased, it is unclear whether the results are
applicable to the other subjects with the same degree of
(nonfamilial) hypercholesterolemia. The medical therapy has
reduced the serum cholesterol concentrations but may not
have yet restored the vasodilatory function of coronary vessels.
In contrast, the present results obtained in the medically
treated patients probably underestimate the effect of FH on
coronary ﬂow reserve. Because only one subject in this study
underwent coronary angiography, we are not able to exclude
the presence of mild anatomic alterations in coronary arteries
not severe enough to cause clinical symptoms. However, it
would be ethically difﬁcult to justify invasive and potentially
risky testing to be performed in an asymptomatic and young
group of subjects. Furthermore, the measured coronary resis-
tance values suggest only a moderate disturbance of coronary
vasomotion in these young patients with FH. We observed
notable interindividual variability of coronary ﬂow reserve in
both study groups (e.g., in some of the control subjects, low
[3] coronary perfusion reserve was detected). The clinical
relevance of these ﬁndings is not known.
Conclusions. Maximal coronary ﬂow and ﬂow reserve after
dipyridamole administration are blunted in young men with
FH. The coronary ﬂow reserve is related to actual serum
cholesterol concentrations, further supporting the concept that
the abnormal serum lipid proﬁle is associated with abnormal
coronary ﬂow response. This study also demonstrates that
quantiﬁcation of myocardial blood ﬂow by PET is a sensitive
tool in detecting abnormalities in coronary vasomotion and in
identifying patient groups with altered coronary vascular reac-
tivity. It provides a potential method to evaluate the treatment
strategies for primary or secondary prevention of coronary
artery disease without large study groups and invasive proce-
dures. However, further studies are needed to evaluate the
clinical signiﬁcance and the prognostic value of these early
changes in coronary ﬂow in asymptomatic patients.
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